Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Kannalife Sciences
Doylestown, Pennsylvania, United Stateskannalife.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Kannalife's lead candidate KLS-13019 has demonstrated improved potency, safety, and bioavailability compared to cannabidiol in pre-clinical models of chemotherapy-induced peripheral neuropathy and neurodegenerative conditions. No clinical data are yet reported, but the program is IND-enabling and supported by multiple NIH grants, with ongoing preclinical validation for neuroprotection and pain management[1][2][3][7].
- Therapeutic areas
- OncologyNeurologyDermatologyGastroenterology
- Modalities
- Small moleculeSynthetic cannabinoid
- Industry
- Biotech
02
Partnerships
National Institutes of Health (NIH)National Institute of Neurological Disorders and Stroke (NINDS)National Institute on Drug Abuse (NIDA)Biotech Inc. (South Park Ventures joint venture)The Michael J. Fox Foundation
Beyond the preview
Go deeper on Kannalife Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kannalife Sciences.